BD FACSLyric: First Domestically Produced High-End Flow Cytometer by BD Medical to Launch in China

Recently, with the acquisition of a medical device registration certificate in China,The localization production project of BD FACSLyric, a flow cytometer under BD (Becton Dickinson) Medical, has entered the final sprint stage and will be launched this summer.This will be BD's first introduction of the production of high-end flow cytometers into China, marking not only a further expansion of the company’s localized production layout in the country but also indicating that the supply and use of high-end flow cytometers in China will become more widespread, thereby driving China’s flow cytometry capabilities into a new era of high standards.

Deng Jianmin, Global Senior Vice President of BD and General Manager of Greater China, stated:"The localized production of the BD FACSLyric flow cytometer marks an important starting point for BD Medical in achieving 'high-end intelligent manufacturing' in China, as well as a significant milestone in the continuous upgrading of our localization strategy. As one of the earliest multinational medical technology companies to establish a presence in the Chinese market, BD Medical has consistently increased its investment in localization over the past 30 years, building a full value chain system that covers manufacturing, R&D innovation, customer service, and training. In addition to BD Medical's own investments, we actively support and connect with ecosystem partners across industry, academia, research, medicine, and government to build a deep national-level empowerment system for world-class innovative technologies, fostering a collaborative and win-win industrial ecosystem."

Wang Tong, Vice President of BD Biosciences Greater China, said:"BD is an innovator and leader in the global flow cytometry field, and the BD FACSLyric flow cytometer is a high-end model in the company’s clinical cytometer lineup. We are highly honored to achieve localized production of this product in China, ensuring stable, fast, efficient, and customized supply while committing to comprehensively drive the expansion of applications and technological upgrades of flow cytometry in China from multiple dimensions—such as scenario adaptation, technological innovation, ecosystem development, and deepening industry-academia-research collaboration. This marks a step into a new era of high standards and deeper integration into China’s healthcare industry chain."

With the localized production of the BD FACSLyric flow cytometer, the large-scale development of high-end flow cytometry in China has taken a crucial first step.In the future, the Chinese value of flow technology will be fully unleashed in terms of technology democratization, local innovation, and ecosystem co-construction.

In terms of technology accessibility, localized production will provide stable and efficient supply for customers in China while significantly reducing waiting times. Additionally, it can offer various configurations tailored to clients across different regions, with varying levels of experience in flow cytometry, meeting diverse needs from basic research to complex clinical testing. Regarding local innovation, localized production will deeply stimulate and empower "Chinese-style innovation" in advanced flow cytometry, including clinical innovation scenarios and diversified cross-disciplinary applications, forming a positive and rapid cycle of "demand-research-application," accelerating the dual achievement of making technology accessible to the public and promoting industrial growth. In terms of ecosystem co-construction, localized production will further enhance the synergistic development advantages of China’s flow cytometry ecosystem. This includes deepening cooperation with local reagent and consumables companies to establish an industry system with Chinese characteristics; collaborating with medical institutions and research institutes to improve clinical research on diseases commonly found in China and expedite the transformation of scientific achievements; as well as providing customized local service support systems and talent cultivation programs, strengthening China’s comprehensive capabilities in industry-academia-research in the field of flow cytometry.

Currently, there are three major drivers behind the global development of flow cytometry technology: flow standardization, automated gating, and efficient quality control. The BD FACSLyric flow cytometer is a highly representative high-end flow cytometer under these trends.

In terms of flow standardization, the BD FACSLyric flow cytometer can achieve full-process standardization from sample preparation to data analysis. Even when running the same experiment across different sites, operators, or instruments, highly reproducible results can still be obtained. For automatic gating, the visual pattern recognition-based automatic gating tool, BD ElastiGate™, is utilized.^1,2, with elastic image registration, has achieved breakthroughs in gating speed, accuracy, and repeatability. The automated gating results are highly similar to manual gating results, making it a key tool for improving laboratory efficiency; furthermore, it achieves automatic gating with minimal training samples, significantly reducing gating time. In terms of efficient quality control, the BD FACSLyric flow cytometer uses a single CS&T bead tube to automatically adjust over 70 parameters, freeing laboratories from cumbersome QC processes while ensuring reliable data and stable instrument performance; additionally, the QC results are linked to universal settings, transforming QC from a mere maintenance tool into a core guarantee for standardized output.

Building on its leading technology and products, BD Medical has also established a reliable quality management system in China for the flow cytometer BD FACSLyric, conducted performance testing, and carried out a series of other important tasks to ensure the equipment's performance aligns with China's unique testing requirements.On April 30, 2025, the flow cytometer BD FACSLyric officially received the medical device registration certificate issued by the Jiangsu Provincial Medical Products Administration (JSMPA), marking a comprehensive acceleration of the localization production project.

BD is a global medical technology company that leads in world health by improving methods of medical discovery, enhancing diagnostic outcomes, and advancing the quality of care. BD supports every frontline healthcare worker with dedication, focusing on developing innovative technologies, services, and solutions to improve clinical treatment for patients and enhance clinical processes for healthcare providers. With 75,000 employees worldwide, BD operates with passion and commitment to provide clinicians with safe and efficient medication delivery processes, assist laboratory scientists in diagnosing diseases more effectively, and empower researchers in developing next-generation diagnostics and treatments. BD has branches in nearly every country, actively collaborating with organizations globally to address the most challenging health issues. Through close cooperation with customers, BD is committed to improving treatment outcomes, reducing healthcare costs, and increasing diagnostic efficiency, thereby enhancing the safety of patients and healthcare workers while expanding access to healthcare.

[1] Automation of flow cytometry data analysis with elastic image registration, Scientific Reports, Nature, 15 May 2025

[2] Automated analysis of flow cytometry data with minimal training files: Research evaluation of an elastic image registration algorithm for TBNK, stem cell enumeration, and lymphoid screening tube assays, PubMed, 2024 Oct 17